A recent study found that up to 40% of trials might be untrustworthy due to flaws in design, improper data collection, and ...

Eli Lilly's oral GLP-1 agonist orforglipron was more effective than Novo Nordisk's recently launched Wegovy pill in a head-to ...

Asahi Kasei has agreed a €780 million (around $920 million) price tag for Wuppertal-based Aicuris, which is hoping for FDA ...

Eisai has a position in kidney cancer with Lenvima (lenvatinib), a kinase inhibitor that is approved for use in combination with MSD's cancer immunotherapy Keytruda (pembrolizumab) as a first-line ...

Pops' decision to step down at the end of July, meanwhile, draws a line under 35 years as CEO of Alkermes, although he will remain chair of the board to help the new CEO, chief operating officer Blair ...

Faruk Capan: AI is incredibly powerful at designing a smarter “front door.” In the GLP-1 space, this could mean the technology could quickly capture medical history, check for comorbidities, analyse ...

Retention has always been a central concern in long-term studies, but obesity trials present a particular challenge. For those assigned to receive the drug candidate in question, the effects are ...

Who controls the narrative, where the money is going, and why patients need to be at the centre of what comes next News headlines, on your Instagram feed, song lyrics, in day-to-day conversation; few ...

As Rare Disease Day approaches, in a special episode of the pharmaphorum podcast, sponsored by AOP Health, we spoke with Melissa Fellner, VP of Global Therapeutic Areas, Commercial Operations, at AOP ...

35Pharma's lead development programme is HS235, an activin receptor-targeting fusion protein that has completed phase 1 ...

Novo Nordisk has turned to pricing as a means to shore up its position in the increasingly competitive market for GLP-1 ...

On today’s podcast, Jonah Comstock is joined by Alice Valder Curran, a partner at Hogan Lovells and a healthcare policy ...